Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions

Current Cardiology Reviews

Volumn 8, Issue 4, 2012, Pages 253-264

  Asghar, O ^a   Alam, U ^a   Hayat, S A ^b   Aghamohammadzadeh, R ^a   Heagerty, A M ^a   Malik, R A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Atrial fibrillation; Epidemiology; Metabolic syndrome; Morbidity; Mortality; Obesity

Indexed keywords

ADIPOCYTOKINE; ANTIARRHYTHMIC AGENT; BISOPROLOL; DIGOXIN; DILTIAZEM; METOPROLOL; PIOGLITAZONE; VERAPAMIL; WARFARIN;

ANTICOAGULANT THERAPY; AUTONOMIC DYSFUNCTION; BARIATRIC SURGERY; BLEEDING; CARDIOVASCULAR RISK; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART VENTRICLE REMODELING; HIGH RISK POPULATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM;

EID: 84867784689     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/157340312803760749     Document Type: Review

References (202)

1. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. New Eng J Med 2008; 359(20): 2105-20.
2. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. New Eng J Med 1999;341(15):1097-105.
3. Asghar O, Al-Sunni A, Khavandi K, et al. Diabetic cardiomyopathy. Clin Sci 2009;116(10):741-60.
4. Sumeray M, Steiner M, Sutton P, et al. Age and obesity as risk factors in perioperative atrial fibrillation. Lancet 1988;2(8608):448.
5. Zacharias A, Schwann TA, Riordan CJ, et al. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation 2005;112(21):3247-3255.
6. Echahidi N, Mohty D, Pibarot P, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation 2007;116(11 Suppl):I213-I219.
7. Girerd N, Pibarot P, Fournier D, et al. Middle-aged men with increased waist circumference and elevated C-reactive protein level are at higher risk for postoperative atrial fibrillation following coronary artery bypass grafting surgery. Eur Heart J 2009; 30(10):1270-1278.
8. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of newonset atrial fibrillation. Jama 2004;292(20):2471-2477.
9. Nicolaou VN, Papadakis JE, Karatzis EN, et al. Impact of the metabolic syndrome on atrial size in patients with new-onset atrial fibrillation. Angiology 2007;58(1):21-25.
10. Umetani K, Kodama Y, Nakamura T, et al. High prevalence of paroxysmal atrial fibrillation and/or atrial flutter in metabolic syndrome. Circulation 2007;71(2):252.
11. Sasson Z, Rasooly Y, Gupta R, et al. Left atrial enlargement in healthy obese: prevalence and relation to left ventricular mass and diastolic function. Can J Cardiol 1996;12(3):257-263.
12. Rutter MK, Parise H, Benjamin EJ, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 2003;107(3):448-454.
13. Garza CA, Pellikka PA, Somers VK, et al. Major weight loss prevents long-term left atrial enlargement in patients with morbid and extreme obesity. Eur J Echocardiogr 2008;9(5):587-593.
14. Hirschler V, Acebo HL, Fernandez GB, et al. Association between left atrial size and measures of adiposity among normal adolescent boys. Pediatr Cardiol 2012;33(2):245-251.
15. Stritzke J, Markus MR, Duderstadt S, et al. The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging the MONICA/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study. J Am Coll Cardiol 2009; 54(21):1982-1689.
16. Frost L, Hune L, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med 2005;118(5):489-495.
17. Wanahita N, Messerli F, Bangalore S, et al. Atrial fibrillation and obesity-results of a meta-analysis. Am Heart J 2008;155(2):310.
18. Tsang TS, Barnes ME, Miyasaka Y, et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J 2008;29(18):2227-2233.
19. Rosengren A, Hauptman PJ, Lappas G, et al. Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. Eur Heart J 2009;30(9):1113-1120.
20. Tedrow UB, Conen D, Ridker PM, et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol 2010;55(21):2319-2327.
21. Badheka AO, Rathod A, Kizilbash MA, et al. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. Am J Med 2010;123(7):646-651.
22. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53(21):1925-1932.
23. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112(17):2735-2752.
24. Watanabe H, Tanabe N, Watanabe T, et al. Metabolic Syndrome and Risk of Development of Atrial Fibrillation: The Niigata Preventive Medicine Study. Circulation 2008;117(10):1255-1260.
25. Nguyen JT, Benditt DG. Atrial fibrillation susceptibility in metabolic syndrome: simply the sum of its parts? Circulation 2008;117(10):1249-1251.
26. Fontes JD, Lyass A, Massaro JM, et al. Insulin resistance and atrial fibrillation (from the Framingham Heart Study). Am J Cardiol 2012;109(1):87-90.
27. Yaggi HK, Concato J, Kernan WN, et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005; 353(19):2034-2041.
28. Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnea. Endocrinology & Metabolism Clinics of North America 2003;32(4):869-894.
29. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165(9):1217-39.
30. Matiello M, Nadal M, Tamborero D, et al. Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients. Europace 2010;12(8):1084-1089.
31. Ng CY, Liu T, Shehata M, et al. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol 2011;108(1):47-51.
32. Dimitri H, Ng M, Brooks AG, et al. Atrial remodeling in obstructive sleep apnea: Implications for atrial fibrillation. Heart Rhythm 2011.
33. Fung JW, Li TS, Choy DK, et al. Severe obstructive sleep apnea is associated with left ventricular diastolic dysfunction. Chest 2002;121(2):422-429.
34. Koehler U, Fus E, Grimm W, et al. Heart block in patients with obstructive sleep apnoea: pathogenetic factors and effects of treatment. Eur Respir J 1998;11(2):434-439.
35. Narkiewicz K, Montano N, Cogliati C, et al. Altered cardiovascular variability in obstructive sleep apnea. Circulation 1998; 98(11):1071-1077.
36. Niroumand M, Kuperstein R, Sasson Z, et al. Impact of obstructive sleep apnea on left ventricular mass and diastolic function. Am J Respir Crit Care Med 2001;163(7):1632-1636.
37. Schafer H, Hasper E, Ewig S, et al. Pulmonary haemodynamics in obstructive sleep apnoea: time course and associated factors. Eur Respir J 1998;12(3):679-684.
38. Tkacova R, Rankin F, Fitzgerald FS, et al. Effects of continuous positive airway pressure on obstructive sleep apnea and left ventricular afterload in patients with heart failure. Circulation 1998;98(21):2269-2275.
39. Narkiewicz K, van de Borne PJ, Cooley RL, et al. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998;98(8):772-776.
40. Schauerte P, Scherlag BJ, Pitha J, et al. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation 2000;102(22):2774-2780.
41. Ghias M, Scherlag BJ, Lu Z, et al. The role of ganglionated plexi in apnea-related atrial fibrillation. J Am Coll Cardiol 2009; 54(22):2075-2083.
42. Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004; 110(4):364-367.
43. Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007;49(5):565-571.
44. Ostgren CJ, Merlo J, Rastam L, et al. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004;6(5):367-374.
45. Nichols GA, Reinier K, Chugh SS. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 2009;32(10):1851-1856.
46. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005;105(3):315-318.
47. Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med 2010;25(8):853-858.
48. Huxley RR, Alonso A, Lopez FL, et al. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart 2012;98(2):133-138.
49. Johansen OE, Brustad E, Enger S, et al. Prevalence of abnormal glucose metabolism in atrial fibrillation: a case control study in 75- year old subjects. Cardiovasc Diabetol 2008;7:28.
50. Huxley RR, Filion KB, Konety S, et al. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011;108(1):56-62.
51. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104(24):2886-2891.
52. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108(24):3006-3010.
53. Marott SC, Nordestgaard BG, Zacho J, et al. Does elevated Creactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J Am Coll Cardiol 2010;56(10):789-795.
54. Batal O, Schoenhagen P, Shao M, et al. Left atrial epicardial adiposity and atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3(3):230-236.
55. Tsao HM, Hu WC, Wu MH, et al. Quantitative analysis of quantity and distribution of epicardial adipose tissue surrounding the left atrium in patients with atrial fibrillation and effect of recurrence after ablation. Am J Cardiol 2011;107(10):1498-1503.
56. Mazurek T, Zhang L, Zalewski A, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003;108(20):2460-2466.
57. Al Chekakie MO, Welles CC, Metoyer R, et al. Pericardial fat is independently associated with human atrial fibrillation. J Am Coll Cardiol 2010;56(10):784-788.
58. Shin SY, Yong HS, Lim HE, et al. Total and interatrial epicardial adipose tissues are independently associated with left atrial remodeling in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2011;22(6):647-655.
59. Thanassoulis G, Massaro JM, O'Donnell CJ, et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ Arrhythm Electrophysiol 2010;3(4):345-350.
60. Wong CX, Abed HS, Molaee P, et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol 2011;57(17):1745-1751.
61. Chang LC, Huang KC, Wu YW, et al. The clinical implications of blood adiponectin in cardiometabolic disorders. J Formos Med Assoc 2009;108(5):353-366.
62. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409(6818):307-312.
63. Mathiasen AB, Henningsen KM, Harutyunyan MJ, et al. YKL-40: a new biomarker in cardiovascular disease? Biomark Med 2010;4(4):591-600.
64. Rathcke CN, Vestergaard H. YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 2009;8:61.
65. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257(1):79-83.
66. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20(6):1595-1599.
67. Ybarra J, Resmini E, Planas F, et al. Relationship between adiponectin and left atrium size in uncomplicated obese patients: adiponectin, a link between fat and heart. Obes Surg 2009;19(9):1324-1332.
68. Rienstra M, Sun JX, Lubitz SA, et al. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am Heart J 2012;163(1):119-24 e1.
69. Gungor H, Ayik MF, Kirilmaz B, et al. Serum resistin level: as a predictor of atrial fibrillation after coronary artery bypass graft surgery. Coronary artery dis 2011;22(7):484-490.
70. Kourliouros A, Karastergiou K, Nowell J, et al. Protective effect of epicardial adiponectin on atrial fibrillation following cardiac surgery. Eur J Cardiothorac Surg 2011;39(2):228-232.
71. Henningsen KM, Therkelsen SK, Johansen JS, et al. Plasma YKL- 40, a new biomarker for atrial fibrillation? Europace 2009;11(8):1032-1036.
72. Henningsen KM, Nilsson B, Johansen JS, et al. Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation. Inflamm Res 2010;59(6):463-469.
73. Shimano M, Shibata R, Tsuji Y, et al. Circulating adiponectin levels in patients with atrial fibrillation. Circ J 2008;72(7):1120-1124.
74. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001;104(2):174-180.
75. Iacobellis G, Di Gioia CR, Cotesta D, et al. Epicardial adipose tissue adiponectin expression is related to intracoronary adiponectin levels. Horm Metab Res 2009;41(3):227-231.
76. Kim YM, Guzik TJ, Zhang YH, et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005;97(7):629-636.
77. Lee S-H, Chen Y-C, Chen Y-J, et al. Tumor necrosis factor-α alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. Life Sci 2007;80(19):1806-1815.
78. Gerritsen J, Dekker JM, TenVoorde BJ, et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care 2001;24(10):1793-1798.
79. Valensi P, Sachs RN, Harfouche B, et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001;24(2):339-343.
80. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007;115(3):387-397.
81. Stevens MJ, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 1998;98(10):961-968.
82. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 2010;53(8):1552-1561.
83. Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. New EngJ Med 2011;364(9):818-828.
84. Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med 2010;25(8):853-858.
85. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352(4):341-350.
86. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998;41(4):416-423.
87. Reichard P, Jensen-Urstad K, Ericsson M, et al. Autonomic neuropathy-a complication less pronounced in patients with Type 1 diabetes mellitus who have lower blood glucose levels. Diabet Med 2000;17(12):860-866.
88. Ziegler D, Weise F, Langen KJ, et al. Effect of glycaemic control on myocardial sympathetic innervation assessed by [123I]metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 1998;41(4):443-451.
89. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New EngJ Med 2003;348(5):383-393.
90. Di Carli MF, Bianco-Batlles D, Landa ME, et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 1999;100(8):813-819.
91. Sacre JW, Franjic B, Jellis CL, et al. Association of Cardiac Autonomic Neuropathy With Subclinical Myocardial Dysfunction in Type 2 Diabetes. JCMG 2010;3(12):1207-1215.
92. Pop-Busui R, Kirkwood I, Schmid H, et al. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 2004;44(12):2368-2374.
93. Dimmer C, Tavernier R, Gjorgov N, et al. Variations of autonomic tone preceding onset of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 1998;82(1):22-25.
94. Zipes DP, Mihalick MJ, Robbins GT. Effects of selective vagal and stellate ganglion stimulation of atrial refractoriness. Cardiovasc Res 1974;8(5):647-655.
95. Spear JF, Moore EN. Influence of brief vagal and stellate nerve stimulation on pacemaker activity and conduction within the atrioventricular conduction system of the dog. Circ Res 1973;32(1):27-41.
96. Goldberger AL, Pavelec RS. Vagally-mediated atrial fibrillation in dogs: conversion with bretylium tosylate. Int J Cardiol 1986;13(1):47-55.
97. van den Berg MP, Hassink RJ, Baljé-Volkers C, et al. Role of the autonomic nervous system in vagal atrial fibrillation. Heart 2003;89(3):333-335.
98. Guler N, Ozkara C, Dulger H, et al. Do cardiac neuropeptides play a role in the occurrence of atrial fibrillation after coronary bypass surgery? Ann Thorac Surg 2007;83(2):532-537.
99. Goette A. The vanishing story of angiotensin II receptor blockers in the treatment of atrial fibrillation. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2011;13(4):451-452.
100. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008;51(8):802-809.
101. Kato T, Yamashita T, Sekiguchi A, et al. What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol 2006;17(8):890-894.
102. Otake H, Suzuki H, Honda T, et al. Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. Int Heart J 2009;50(5):627-641.
103. Schmid H, Forman LA, Cao X, et al. Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin-induced diabetic rats: implications for cardiac sympathetic dysinnervation complicating diabetes. Diabetes 1999;48(3):603-608.
104. Musial DC, de Magalhães Galvão K, Miranda-Ferreira R, et al. Alteration of Purinergic Neurotransmission in Isolated Atria of Streptozotocin-induced Diabetic Rats. J Cardiovasc Pharmacol 2012;59(2):158-164.
105. Lok NS, Lau CP. Abnormal vasovagal reaction, autonomic function, and heart rate variability in patients with paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 1998;21(2):386-395.
106. van den Berg MP, Hassink RJ, Tuinenburg AE, et al. Impaired autonomic function predicts dizziness at onset of paroxysmal atrial fibrillation. Int J Cardiol 2001;81(2-3):175-180.
107. Khand AU, Rankin AC, Cleland JGF, et al. The assessment of autonomic function in chronic atrial fibrillation: description of a non-invasive technique based on circadian rhythm of atrioventricular nodal functional refractory periods. Europace 2006;8(11):927-934.
108. Voulgari C, Tentolouris N, Stefanadis C. The ECG vertigo in diabetes and cardiac autonomic neuropathy. Exp Diabetes Res 2011;2011:687624.
109. Bissinger A, Grycewicz T, Grabowicz W, et al. The effect of diabetic autonomic neuropathy on P-wave duration, dispersion and atrial fibrillation. Arch Med Sci 2011;7(5):806-12.
110. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69(6):546-54.
111. Dentali F, Squizzato A, Ageno W. The metabolic syndrome as a risk factor for venous and arterial thrombosis. Semin Thromb Hemost 2009;35(5):451-7.
112. Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97(11):2601-10.
113. Palomo I, Moore-Carrasco R, Alarcon M, et al. Pathophysiology of the proatherothrombotic state in the metabolic syndrome. Front Biosci (Schol Ed) 2010;2:194-208.
114. Hulthe J, Bokemark L, Wikstrand J, et al. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 2000;20(9):2140-7.
115. Bowles LK, Cooper JA, Howarth DJ, et al. Associations of haemostatic variables with body mass index: a community-based study. Blood Coagul Fibrinolysis 2003;14(6):569-73.
116. Darvall KA, Sam RC, Silverman SH, et al. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007;33(2):223-33.
117. Vazquez LA, Pazos F, Berrazueta JR, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 2005;90(1):316-22.
118. Lansbury AJ, Grant PJ, Catto AJ. Atherothrombotic risk factors in subjects with a family history of stroke. Cerebrovasc Dis 2002;14(3-4):153-60.
119. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000;106(4):453-8.
120. Mills JD, Mansfield MW, Grant PJ. Factor XIII-circulating levels and the Val34Leu polymorphism in the healthy male relatives of patients with severe coronary artery disease. Thromb Haemost 2002;87(3):409-14.
121. Sola E, Navarro S, Medina P, et al. Activated protein C levels in obesity and weight loss influence. Thromb Res 2009;123(5):697-700.
122. Godsland IF, Crook D, Proudler AJ, et al. Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome. J Clin Endocrinol Metab 2005;90(1):190-7.
123. Samad F, Pandey M, Loskutoff DJ. Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci USA 1998;95(13):7591-6.
124. Atsuchi N, Nishida T, Marutsuka K, et al. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. Circulation 2001;103(4):570-5.
125. Sajadi S, Ezekowitz MD, Dhond A, et al. Tissue factor pathway inhibitors as a novel approach to antithrombotic therapy. Drug News Perspect 2003;16(6):363-9.
126. Morange PE, Renucci JF, Charles MA, et al. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thromb Haemost 2001;85(6):999-1003.
127. Dentali F, Romualdi E, Ageno W. The metabolic syndrome and the risk of thrombosis. Haematologica 2007;92(3):297-9.
128. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004;24(6):1015-22.
129. Mertens I, Ballaux D, Funahashi T, et al. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation. Thromb Haemost 2005;94(6):1190-5.
130. Palomo I, Moore-Carrasco R, Alarcon M, et al. Pathophysiology of the proatherothrombotic state in the metabolic syndrome. Front Biosci (Schol Ed) 2009;2:194-208.
131. Eriksson P, Reynisdottir S, Lonnqvist F, et al. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998;41(1):65-71.
132. Alessi MC, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46(5):860-7.
133. Mavri A, Alessi MC, Bastelica D, et al. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia 2001;44(11):2025-31.
134. Stegenga ME, van der Crabben SN, Blumer RM, et al. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood 2008;112(1):82-9.
135. Rao AK, Chouhan V, Chen X, et al. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 1999;48(5):1156-61.
136. Khechai F, Ollivier V, Bridey F, et al. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation. Arterioscler Thromb Vasc Biol 1997;17(11):2885-90.
137. Min C, Kang E, Yu SH, et al. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. Diabetes Res Clin Pract 1999;46(3):197-202.
138. Ceriello A, Giugliano D, Quatraro A, et al. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 1988;31(12):889-91.
139. Reid HL, Vigilance J, Wright-Pascoe RA, et al. The influence of persistent hyperglycaemia on hyperfibrinogenaemia and hyperviscosity in diabetes mellitus. West Indian Med J 2000; 49(4):281-4.
140. Fain JN, Madan AK. Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor 1 but not interleukin-6 release by human adipocytes. Metabolism 2005;54(2):220-6.
141. Vericel E, Januel C, Carreras M, et al. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes 2004;53(4):1046-51.
142. Aghamohammadzadeh R, Withers SB, Lynch FM, et al. Perivascular adipose tissue from human systemic and coronary vessels: The emergence of a new pharmacotherapeutic target. Br J Pharmacol 2011.
143. Nakata M, Yada T, Soejima N, et al. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999;48(2):426-9.
144. Kato H, Kashiwagi H, Shiraga M, et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006;26(1):224-30.
145. Shoji T, Koyama H, Fukumoto S, et al. Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis. 2006;188(1):190-5.
146. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008;99(2):295-304.
147. Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med 2010;123(6):484-8.
148. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2010;12(10):1360-420.
149. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263-72.
150. Tang RB, Liu XH, Kalifa J, et al. Body mass index and risk of left atrial thrombus in patients with atrial fibrillation. Am J Cardiol 2009;104(12):1699-703.
151. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151(3):713-9.
152. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2006;8(9):651-745.
153. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):546S-592S.
154. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1(2):84-91.
155. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010;123(7):638-645e4.
156. Schirmer SH, Baumhakel M, Neuberger HR, et al. Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. J Am Coll Cardiol 2010;56(25):2067-76.
157. Xu G, Chen J, Jing G, et al. Preventing beta-Cell Loss and Diabetes With Calcium Channel Blockers. Diabetes 2012;61(4):848-56.
158. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a metaanalysis. Circulation 2000;101(10):1138-44.
159. Frick M, Frykman V, Jensen-Urstad M, et al. Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol 2001;24(3):238-44.
160. Elhendy A, Gentile F, Khandheria BK, et al. Predictors of unsuccessful electrical cardioversion in atrial fibrillation. Am J Cardiol 2002;89(1):83-6.
161. Blich M, Edoute Y. Electrical cardioversion for persistent or chronic atrial fibrillation: outcome and clinical factors predicting short and long term success rate. Intern J Cardiol 2006;107(3):389-94.
162. Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgraduate Med J 2006;82(966):280-4.
163. Saliba W, Juratli N, Chung MK, et al. Higher energy synchronized external direct current cardioversion for refractory atrial fibrillation. J Am Coll Cardiol 1999;34(7):2031-4.
164. Botto GL, Politi A, Bonini W, et al. External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements. Heart 1999;82(6):726-30.
165. Mehdirad AA, Clem KL, Love CJ, et al. Improved clinical efficacy of external cardioversion by fluoroscopic electrode positioning and comparison to internal cardioversion in patients with atrial fibrillation. Pacing and clinical electrophysiology: PACE 1999;22(1 Pt 2):233-7.
166. Schmitt C, Alt E, Plewan A, et al. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol 1996;28(4):994-9.
167. Jais P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008;118(24):2498-505.
168. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am College Cardiol 2006;48(11):2340-7.
169. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293(21):2634-40.
170. Noheria A, Kumar A, Wylie JV, Jr., et al. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med 2008;168(6):581-6.
171. Piccini JP, Lopes RD, Kong MH, et al. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circulation Arrhythmia and electrophysiology. 2009;2(6):626-33.
172. Nair GM, Nery PB, Diwakaramenon S, et al. A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. J Cardiovasc electrophysiol 2009;20(2):138-44.
173. Reynolds MR, Walczak J, White SA, et al. Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs. Circ Cardiovasc Qual Outcomes 2010; 3(6):615-23.
174. Dewire J, Calkins H. State-of-the-art and emerging technologies for atrial fibrillation ablation. Nat Rev Cardiol 2010;7(3):129-38.
175. Cappato R, Calkins H, Chen SA, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 2009;53(19):1798-803.
176. Ouyang F, Tilz R, Chun J, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 2010;122(23):2368-77.
177. Hindricks G, Piorkowski C, Tanner H, et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 2005;112(3):307-13.
178. Chao TF, Suenari K, Chang SL, et al. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. Am J Cardiol 2010;106(11):1615-20.
179. Forleo GB, Mantica M, De Luca L, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J cardiovasc electrophysiol 2009;20(1):22-8.
180. Tang RB, Dong JZ, Liu XP, et al. Safety and efficacy of catheter ablation of atrial fibrillation in patients with diabetes mellitus-single center experience. J interv card electrophysiol 2006;17(1):41-6.
181. Park JH, Pak HN, Kim SK, et al. Electrophysiologic characteristics of complex fractionated atrial electrograms in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2009;20(3):266-72.
182. Cai L, Yin Y, Ling Z, et al. Predictors of late recurrence of atrial fibrillation after catheter ablation. Int J Cardiol 2011.
183. Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. J interv card electrophysiol 2005;13(3):181-93.
184. Boos C, Ritzema J, More RS. A short course of oral amiodarone improves sinus rhythm maintenance post-cardioversion for atrial fibrillation. Heart 2004;90(9):1063-4.
185. Korantzopoulos P, Kolettis TM, Galaris D, et al. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007;115(2):135-43.
186. Shimano M, Shibata R, Inden Y, et al. Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation. Heart rhythm 2009;6(7):935-40.
187. Kumar S, Sutherland F, Morton JB, et al. Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. Heart rhythm 2011.
188. Boos CJ, Lip GY. Inflammation and atrial fibrillation: cause or effect? Heart 2008;94(2):133-4.
189. Richter B, Derntl M, Marx M, et al. Therapy with angiotensinconverting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. AmHeart J 2007;153(1):113-9.
190. Patel D, Mohanty P, Di Biase L, et al. The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females. Europace 2010;12(3):322-30.
191. Tayebjee MH, Creta A, Moder S, et al. Impact of angiotensinconverting enzyme-inhibitors and angiotensin receptor blockers on long-term outcome of catheter ablation for atrial fibrillation. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2010;12(11):1537-42.
192. Nodari S, Triggiani M, Campia U, et al. n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. Circulation 2011;124(10):1100-6.
193. Farquharson AL, Metcalf RG, Sanders P, et al. Effect of dietary fish oil on atrial fibrillation after cardiac surgery. Am J Cardiol 2011;108(6):851-6.
194. Kowey PR, Reiffel JA, Ellenbogen KA, et al. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA 2010;304(21):2363-72.
195. Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. AmJ Clin Nutr 2005;81(1):50-4.
196. Gu J, Liu X, Wang X, et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2011;13(9):1256-61.
197. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 2004;27(10):982-91.
198. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010;104(1):49-60.
199. Qayyum R, Adomaityte J. Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels. Am J Cardiol 2006;97(5):655-8.
200. Heneghan HM, Meron-Eldar S, Brethauer SA, et al. Effect of Bariatric Surgery on Cardiovascular Risk Profile. Am J Cardiol 2011.
201. Nicholas C, May R. HealthGrades Fifth Annual Bariatric Surgery Trends in American Hospitals Study 2010.
202. Sola E, Vaya A, Espana F, et al. Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism. Thromb Res 2008;122(3):320-7.